Coffee (KC)

La vendita allo scoperto per Kingsoft Cloud Hldgs dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Kingsoft Cloud Hldgs. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Kingsoft Cloud Hldgs (NASDAQ:KC) Azioni, Report sulle vendite allo scoperto

Kingsoft Cloud Hldgs

Kingsoft Cloud Holdings

Kingsoft Cloud Holdings Ltd is an independent cloud service provider in China. It provides integrated cloud-based services including cloud computing, storage, and delivery. Its products and services are Safety, database, AI, hybrid cloud and others. Its solutions are medical, government affairs, finance, media, Educate, game, Transportation and Logistics, Audio, and video.

Kingsoft Cloud Holdings Limited - American Depositary Shares

Kingsoft Cloud Holdings Ltd

KraneShares Trust KraneShares China Alpha Index ETF

Series Portfolio Trust Subversive Food Security ETF

KraneShares California Carbon Allowance Strategy ETF

KUTCHO COPPER CORP ORD by Kutcho Copper Corp.

Kutcho Copper Corp

KCCPAD

KIMBERLY-CLARK DE MEX A by Kimberly-Clark de Mexico, S.A.B de C.V.

Kimberly - Clark de Mexico SAB de CV

KIMBERLY-CLARK MEX S/ADR by Kimberly-Clark de Mexico, S.A.B de C.V.

SPDR S&P Capital Markets ETF

KCE ELECTRONICS PUB ADR by KCE Electronics Pub Co Ltd.

KCE Electronics PCL

KENSINGTON CAPITAL ACQUISITION CORP V ORD

KUMIAI CHEMICAL INDS by Kumiai Chemical Industry Co., Ltd.

Kumiai Chemical Industry Co Ltd

KECK SENG INVESTMENTS by Keck Seng Investments

Keck Seng Investments (Hong Kong) Ltd

KINGSOFT CLOUD HLDGS LTD by Kingsoft Cloud Holdings Limited

KANSAS CITY LIFE INS NEW by Kansas City Life Insurance Co.

Kansas City Life Insurance Co

KCM Holdings Corp

KEY CAPITAL CORP by Key Capital Corporation

Key Capital Corp

Kindcard Inc

KuCoin Token

KraneShares Trust KraneShares Sustainable Ultra Short Duration Index ETF

Citigroup analyst Anthony Pettinari reinstates Berry Global Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BERY#NYSE">BERY</a>) with a Neutral and announces $76 price target.

News

Price Target

Initiation

Analyst Ratings

BERY

Citigroup Reinstates Neutral on Berry Global Gr, Announces $76 Price Target

Macy's Says November Comparable Sales Are Trending Ahead Of Q3 Levels Across Nameplates

Guidance

Macy's Delays Q3 Earnings Release And Conference Call; Reports Preliminary Net Sales Decrease Of 2.4% To $4.742Bn, With Comparable Sales Down 2.4% On An Owned Basis

Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) reported quarterly earnings of $0.49 per share which beat the analyst consensus estimate of $0.47 by 4.26 percent. This is a 2.08 percent increase over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $1.610 billion which beat the analyst consensus estimate of $1.579 billion by 1.98 percent. This is a 3.07 percent increase over sales of $1.562 billion the same period last year.

Earnings

Earnings Beats

BBWI

Bath & Body Works Q3 2024 Adj. EPS $0.49 Beats $0.47 Estimate, Sales $1.610B Beat $1.579B Estimate

Citigroup analyst Keith Horowitz downgrades M&amp;T Bank (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTB#NYSE">MTB</a>) from Buy to Neutral and raises the price target from $220 to $230.

Downgrades

Citigroup Downgrades M&T Bank to Neutral, Raises Price Target to $230

Needham analyst Serge Belanger reiterates Viridian Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRDN#NASDAQ">VRDN</a>) with a Buy and maintains $38 price target.

Reiteration

VRDN

Needham Reiterates Buy on Viridian Therapeutics, Maintains $38 Price Target

Nu Holdings Ltd. ("Nu Holdings"of "Company") informs its shareholders and the market that the Financial Superintendence of Colombia ("SFC") has formally approved the merger of its Colombian entity Nu Colombia S.A. into Nu. Colombia Compañía de Financiamiento S.A..
The merger, which consolidates the accounts and operations in the country into one single entity (Nu. Colombia Compañía de Financiamiento S.A.) supervised by the SFC, reinforces the Company's long-term vision and commitment to Colombia and will allow the expansion of its portfolio of products and services in the future.

Nu Holdings Consolidates Colombian Operations, Expanding Future Financial Services

Needham analyst Scott Berg reiterates Workday (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDAY#NASDAQ">WDAY</a>) with a Buy and maintains $300 price target.

WDAY

Needham Reiterates Buy on Workday, Maintains $300 Price Target

Freightos Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGO#NASDAQ">CRGO</a>), a leading vendor-neutral digital booking and payment platform for the international freight industry, today announced that Ran Shalev, Chief Financial Officer, has decided to conclude his tenure effective December 31, 2024, to pursue another role. The company is in the process of a search for a successor. In order to ensure continuity, Mr. Shalev has agreed following his departure to actively assist with ongoing operations and with handover throughout Q1.
&nbsp;
Mr. Shalev has served as Freightos' CFO since 2016, overseeing the company's financial operations during a transformative period that included its public listing on Nasdaq, the successful execution of multiple strategic acquisitions, and consistent growth in revenue and transaction volumes.

Management

CRGO

Freightos To Deaprt As CFO Effective December 31 To Pursue Another Job, Company In Process Of Finding A Successor

<ul>
<li>Amglidia is a proprietary, patented liquid product that was developed for the treatment of neonatal diabetes mellitus by AMMTeK, a French biotechnology company. The product was approved by the EMA in 2018.&nbsp;</li>
<li>The product has already been granted Orphan Drug Designation by the U.S. FDA. Neonatal diabetes mellitus is a rare condition estimated to impact approximately 300 patients in the United States.&nbsp;</li>
<li>Currently, there are no FDA-approved oral treatment options and as a result, U.S. patients frequently either rely on compounded products that are not FDA-approved or administer products off-label by making homemade suspensions.</li>
<li>AMMTeK has conducted a post-approval study tracking five years of real-world safety and efficacy in European patients, which will be used to support Eton's NDA submission. Eton plans to hold a meeting with the FDA in the first quarter of 2025 and anticipates submitting an NDA for the product in 2026.</li>
</ul>

Health Care

General

ETON

Eton Pharmaceuticals Has Acquired The Us Rights To Amglidia (Glyburide Oral Suspension, Known As Glibenclamide In Europe) For Neonatal Diabetes Mellitus From AMMTeK, Potential US Marketing Application Submission Expected In 2026

Loop Capital analyst Garik Shmois downgrades Eagle Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXP#NYSE">EXP</a>) from Buy to Hold and maintains the price target from $315 to $315.

Loop Capital Downgrades Eagle Materials to Hold, Maintains Price Target to $315

Wolfe Research analyst Andrew Rosivach upgrades Jones Lang LaSalle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JLL#NYSE">JLL</a>) from Peer Perform to Outperform and announces $353 price target.

Upgrades

Wolfe Research Upgrades Jones Lang LaSalle to Outperform, Announces $353 Price Target

Merck (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), known as MSD outside of the United States and Canada, announced today positive topline results from the Phase 3 ZENITH study evaluating WINREVAIR (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO&#x2A; Group 1) functional class (FC) III or IV at high risk of mortality. ZENITH met its primary endpoint of time to first morbidity or mortality event (all-cause death, lung transplantation, or PAH worsening related hospitalization of ≥ 24 hours). In the study, WINREVAIR demonstrated a statistically significant and clinically meaningful reduction in the risk of morbidity or mortality events compared to placebo, both on top of background PAH therapy. Based on the strength of these results, an independent data monitoring committee has recommended ZENITH be stopped early and all participants be offered the opportunity to receive WINREVAIR through the SOTERIA open-label extension study. In preliminary assessment, adverse events and serious adverse events were balanced between the treatment groups.
"PAH is a serious, progressive disease with a high incidence of morbidity and mortality," said Dr. Eliav Barr, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories. "Based on the primary endpoint demonstrating overwhelming efficacy, all ZENITH study participants will be offered the opportunity to receive WINREVAIR. These findings are impressive, set a high evidentiary bar for studies of future candidates developed for the treatment of PAH and support the potential of WINREVAIR to be practice-changing in the management of PAH."
"The ZENITH trial was designed to evaluate whether the addition of WINREVAIR, an activin signaling inhibitor, could reduce the risk of death, lung transplantation, or PAH hospitalizations for patients living with advanced PAH," said Dr. Vallerie McLaughlin&#x2A;&#x2A;, Kim A Eagle MD Endowed Professor of Cardiovascular Medicine and Director, Pulmonary Hypertension Program, University of Michigan in Ann Arbor. "This is the first study in PAH in which the interim analysis led to an early conclusion of the study due to overwhelming efficacy. WINREVAIR has brought significant optimism to the field, and we thank the investigators and patients for being part of this important study."
WINREVAIR is currently approved in the U.S. and 36 countries based on the results from the Phase 3 STELLAR trial. Most recently, in November of this year, WINREVAIR was submitted for approval in Japan based on the STELLAR trial and results from an open-label Phase 3 study in Japanese patients.
Results from ZENITH will be presented at an upcoming medical meeting and will be submitted to regulatory authorities.

Merck's WINREVAIR Achieves Results in PAH Study, Trial Ends Early on Efficacy

Wolfe Research analyst Andrew Rosivach downgrades Newmark Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRK#NASDAQ">NMRK</a>) from Outperform to Peer Perform.

NMRK

Wolfe Research Downgrades Newmark Group to Peer Perform

Barclays analyst Ramsey El-Assal initiates coverage on MARA Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) with a Equal-Weight rating and announces Price Target of $27.

MARA

Barclays Initiates Coverage On MARA Holdings with Equal-Weight Rating, Announces Price Target of $27

Barclays analyst Lydia Rainforth upgrades Equinor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>) from Equal-Weight to Overweight.

EQNR

Barclays Upgrades Equinor to Overweight

EnLink Midstream, LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENLC#NYSE">ENLC</a>) shares traded higher premarket on Monday after it disclosed a merger deal with ONEOK, Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKE#NYSE">OKE</a>) for $4.3 billion.
As per the deal, each EnLink common unit not owned by ONEOK will be exchanged for <a target="_blank" href="https://www.benzinga.com//node/42155913" rel="noreferrer noopener">0.1412 shares of ONEOK stock.</a>
This exchange ratio reflects EnLink&#8217;s closing price of $15.75 on November 22, 2024, divided by ONEOK&#8217;s 10-day volume-weighted average price (VWAP).
ONEOK will issue approximately 37 million shares, representing about 6% of its total shares outstanding after the transaction.
ONEOK, which holds approximately 44% of EnLink&#8217;s common units, has committed to voting in favor of the transaction.
The transaction, subject to customary closing conditions, is expected to close in the first quarter of 2025.
The merger&#8217;s completion requires approval from a majority of EnLink&#8217;s outstanding common units, including those owned by ONEOK, and satisfaction of other customary closing conditions.
Pierce H. Norton II, ONEOK president and chief executive officer, said, &#8220;This tax-free transaction to acquire the remaining outstanding EnLink units is expected to be accretive to ONEOK shareholders and provide EnLink unitholders with significantly greater trading liquidity and an attractive dividend yield.&#8221;&nbsp;&nbsp;
In October 15, 2024, ONEOK disclosed the successful completion of its acquisition of Global Infrastructure Partners&#8217; (GIP) entire interest in EnLink for a total cash <a target="_blank" href="https://www.benzinga.com/markets/equities/24/08/40626128/oneok-spends-3b-on-enlink-midstream-stake-2-6b-on-medallion" rel="noreferrer noopener">consideration of approximately&nbsp;$3.3 billion</a>.
Investors can gain exposure to the OKE stock via&nbsp;Global X MLP &amp; Energy Infrastructure ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLPX#NYSE">MLPX</a>) and Tortoise North American Pipeline ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPYP#NYSE">TPYP</a>).
Price Action: ENLC shares are up 1.27% at $15.95 premarket at the last check Monday.
Photo via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/global/24/11/42118286/7-us-natural-gas-stocks-to-watch-as-henry-hub-prices-surge-50-in-november" target="_blank" rel="noreferrer noopener">7 US Natural Gas Stocks To Watch As Henry Hub Prices Surge 50% In November</a></li>
</ul>

Equities

Mid Cap

ENLC

MLPX

TPYP

ONEOK Bolsters Portfolio With EnLink Acquisition, $4.3 Billion Deal Unveiled

Wedbush analyst Daniel Ives maintains Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Outperform and raises the price target from $325 to $375.

Wedbush Maintains Outperform on Salesforce, Raises Price Target to $375

UHAL

U-Haul Expands Kingsport Operations With Acquisition Of All Season Storage On Fort Henry Drive

JP Morgan analyst Domingos Falavina upgrades Banco Santander (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSBR#NYSE">BSBR</a>) from Neutral to Overweight and lowers the price target from $7 to $6.

BSBR

JP Morgan Upgrades Banco Santander to Overweight, Lowers Price Target to $6

Here's the major earnings before the open tomorrow

Kingsoft Cloud GAAP EPS of -$0.04, revenue of $268.7M misses by $4.87M

Sees profitability improving in Q4. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>...

Kingsoft Cloud sees accelerated growth rate for Q4 revenues

Kingsoft Cloud Holdings (KC) has released an update. Kingsoft Cloud Holdings has reported significant growth in its third-quarter financial results...

Kingsoft Cloud Reports Strong Q3 Growth Fueled by AI

Kingsoft Cloud Holdings Limited (KC) Q3 2024 Earnings Call Transcript

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Walmart (WMT) provided a "beat and rai...

Walmart higher, Lowe's lower after earnings: Morning Buzz

Kingsoft Cloud Holdings Ltd. ( ($KC) ) has released its Q3 earnings. Here is a breakdown of the information Kingsoft Cloud Holdings Ltd. presented ...

Kingsoft Cloud Reports Strong Q3 2024 Growth

In a report released yesterday, Daley Li from Bank of America Securities reiterated a Hold rating on Kingsoft Cloud Holdings Ltd (3896 – Research R...

Cautious Optimism for Kingsoft Cloud Amid AI-Driven Growth and Cash Flow Challenges

Nomura upgraded Kingsoft Cloud (KC) to Buy from Neutral with a price target of $6.70, up from $2.30. The company's Q3 results underpin its business...

Kingsoft Cloud upgraded to Buy from Neutral at Nomura

Kingsoft Cloud rises after Nomura upgrades on AI and Xiaomi ecosystem demand

AAPL

ACRS

AMZN

APLS

BLNK

BNTX

CART

CHPT

DNMR

EDRY

ESLT

FUTU

GOOG

GOOGL

IIIV

INCY

INTC

JNPR

JOBY

OCSL

SABR

SMCI

SNEJF

SONY

UBER

VIPS

WKHS

XIACF

XIACY

XPEV

Press Releases

Kingsoft Cloud Announces Results of Extraordinary General Meeting

Kingsoft Cloud to Report Fourth Quarter and Fiscal Year 2023 Financial Results on March 20, 2024

Kingsoft Cloud Announces Unaudited Fourth Quarter and Fiscal Year 2023 Financial Results

Kingsoft Cloud Files Annual Report on Form 20-F for Fiscal Year 2023 and Releases 2023 Environmental, Social and Governance Report

Kingsoft Cloud to Report First Quarter 2024 Financial Results on May 22, 2024

Kingsoft Cloud Announces Unaudited First Quarter 2024 Financial Results

Kingsoft Cloud to Report Second Quarter 2024 Financial Results on August 20, 2024

Kingsoft Cloud Announces Unaudited Second Quarter 2024 Financial Results

Kingsoft Cloud to Report Third Quarter 2024 Financial Results on November 19, 2024

Kingsoft Cloud Announces Unaudited Third Quarter 2024 Financial Results with Accelerated Revenue Growth and Robust Expansion of Gross and EBITDA profit

Comments

Kingsoft Cloud Hldgs

Vendite allo scoperto

Kingsoft Cloud Hldgs (NASDAQ:KC) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO